These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 8691835)

  • 21. Cytokeratin serum biomarkers in patients with colorectal cancer.
    Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
    Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The value of tumor markers in colorectal cancer].
    Peters KM; Grundmann R
    Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
    Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
    Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEA and CA 19-9 as prognostic indexes in colorectal cancer.
    Forones NM; Tanaka M
    Hepatogastroenterology; 1999; 46(26):905-8. PubMed ID: 10370636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer].
    Sandelewski A; Kokocińska D; Partyka R; Kocot J; Starzewski J; Chanek I; Jałowiecki P
    Pol Merkur Lekarski; 2005 Jun; 18(108):647-50. PubMed ID: 16124375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
    Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
    Gebauer G; Müller-Ruchholtz W
    Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
    Lindmark G; Kressner U; Bergström R; Glimelius B
    Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
    Putzki H; Reichert B; Jablonski M; Heymann H
    Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
    Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Arginase as a marker of cancerogenesis. III. Comparison of arginase activity with CEA and Ca 19-9 in liver metastases of colorectal cancer].
    Porembska Z; Skwarek A; Chrzanowska A; Mielczarek M; Nyckowski P; Barańczyk-Kuźma A
    Pol Merkur Lekarski; 2004 Jan; 16(91):31-3. PubMed ID: 15074017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.